What this study is
The purpose of this study is to find out about the quality of life and health in patients who had retinoblastoma in one eye (unilateral retinoblastoma), who either received treatment with chemotherapy injected directly into an artery leading to the eye (intra-arterial chemotherapy) or removal of the eye (enucleation). By quality of life, the investigators mean how the participants are feeling about being satisfied with things in their life, including, physical health, emotional health, and their ability to carry out daily activities. The investigators want to see if either treatment option would affect quality of life differently. The investigators hope that this information will help us provide better care to future children with retinoblastoma and better follow-up care for survivors of retinoblastoma.
What's being tested
- BASC-3 survey
Intervention · BEHAVIORAL
- PROMIS survey
Intervention · BEHAVIORAL
Both interventions
A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
Study details
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Survivors of Unilateral Retinoblastoma
- Enrolling
- 120 people
- Starts
- 2018-08-31
- Est. completion
- 2027-08
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 8 Years – 17 YearsSex ALLHealthy volunteers Not acceptedAll participants
You may qualify if
- Ability to speak and understand English or Spanish
- Diagnosis of unilateral retinoblastoma at any age, confirmed by the enrolling institution
- Treatment of retinoblastoma between 2006 or later
- Patients must between the age of 8-17 years old
- At least 1 year since completion of all cancer-directed therapy
- Treatment with enucleation of the affected eye or intra-arterial chemotherapy
You can't join if
- Patients, or parents of patients, treated with both enucleation and intra-arterial chemotherapy are not eligible
Parent of patient
You may qualify if
- Ability to speak and understand English or Spanish
- Ability to confirm that he or she is the parent of a child treated for unilateral retinoblastoma who meets the eligibility criteria listed above
- Ability to provide informed consent
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openMemorial Sloan Kettering Cancer Center
New York, New York, United States
Texas Children's Hospital (Data Collection)
Houston, Texas, United States
Study team
Sponsor
Memorial Sloan Kettering Cancer Center
Study ID 18-397
Principal investigator
Laura Cimini, PhD
Memorial Sloan Kettering Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.